A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients with Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Immune Design Corp.
Start Date
April 1, 2016
End Date
March 31, 2021
Administered By
Duke Cancer Institute
Awarded By
Immune Design Corp.
Start Date
April 1, 2016
End Date
March 31, 2021